Deutsch English Français

Contact

EP1435988

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1435988

EP1435988 - IMPROVED USE OF ANTITUMORAL COMPOUND IN CANCER THERAPY [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 15.10.2010 Database last updated on 03.10.2024
Most recent event Tooltip	15.10.2010	Application deemed to be withdrawn	published on 17.11.2010 [2010/46]
Applicant(s)	For all designated states Pharmamar S.A. c/ Calera 3 28760 Tres Cantos / ES
	[2004/29]
Inventor(s)	01 / JIMENO, Jose Camino Alto 40 28792 Miraflores de la Sierra, Madrid / ES
	02 / RUIZ Casado, Ana Calle San Sebastian 2-1 4 28230 Las Rozas / ES
	03 / LOPEZ LAZARO, Luis Calle Ferrer del Rio 3, Escalera B,3 2 28028 Madrid / ES
	04 / ROWINSKY, Eric Institute for Drug Development Suite 700 8122 Datapoint Drive San Antonio, TX 78229 / US
	05 / HIDALGO, Manuel The Johns Hopkins Oncology Ctr. Bunting Blaustein Cancer R. Bld 1-M88 1650 Orleans Baltimore, MD 21231-1 / US
	[2004/41]
Former [2004/29]	01 / JIMENO, Jose Pharmamar S.A. c/Calera, 3 E-28760 Tres Cantos / ES
	02 / RUIZ Casado, Ana Pharmamar S.A. c/Calera, 3 E-28760 Tres Cantos / ES
	03 / LOPEZ Lazaro, Luis Pharmamar S.A. c/Calera, 3 E-28760 Tres Cantos / ES
	04 / ROWINSKY, Eric Institute for Drug Development Suite 700 8122 Datapoint Drive San Antonio, TX 78229 / US
	05 / HIDALGO, Manuel The Johns Hopkins Oncology Ctr. Bunting Blaustein Cancer R. Bld 1-M88 1650 Orleans Baltimore, MD 21231-1 / US
Representative(s)	Ruffles, Graham Keith Marks & Clerk LLP 62-68 Hills Road Cambridge CB2 1LA / GB
	[N/P]
Former [2008/33]	Ruffles, Graham Keith Marks & Clerk 62-68 Hills Road Cambridge CB2 1LA / GB
Former [2004/29]	Ruffles, Graham Keith Marks & Clerk, 66-68 Hills Road Cambridge, Cambridgeshire CB2 1LA / GB
Application number, filing date	02780496.2	21.10.2002
	[2004/29]
	WO2002US33548
Priority number, date	US20010348414P	19.10.2001 Original published format: US 348414 P
	[2004/29]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO03039571
	Date:	15.05.2003
	Language:	EN
	[2003/20]
	Type:	A1 Application with search report
	No.:	EP1435988
	Date:	14.07.2004
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 15.05.2003 takes the place of the publication of the European patent application.
	[2004/29]
Search report(s)	International search report - published on:	US	15.05.2003
	(Supplementary) European search report - dispatched on:	EP	12.12.2007
Classification	IPC:	A61K31/4995, A61P35/00, // A61K45/06	[2008/02]
	CPC:	A61K31/704 (EP,US); A61K31/495 (KR); A61K31/198 (EP,US); A61K31/4995 (EP,US); A61K33/243 (EP,US); A61K45/06 (EP,US); (+) A61P35/00 (EP); A61P43/00 (EP) (-)
	C-Set:	A61K31/198, A61K2300/00 (EP,US); A61K31/704, A61K2300/00 (US,EP); A61K33/24, A61K2300/00 (US,EP)
	Former IPC [2004/29]	A61K38/00, A61K38/16
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR [2004/29]
Extension states	AL	02.04.2004
	LT	02.04.2004
	LV	02.04.2004
	MK	02.04.2004
	RO	02.04.2004
	SI	02.04.2004
Title	German:	VERBESSERTE VERWENDUNG EINER ANTITUMORALEN VERBINDUNG IN DER KREBSTHERAPIE	[2004/29]
	English:	IMPROVED USE OF ANTITUMORAL COMPOUND IN CANCER THERAPY	[2004/29]
	French:	UTILISATION AMELIOREE DE COMPOSE ANTI-TUMORAL DANS LE TRAITEMENT DES CANCERS	[2004/29]
Entry into regional phase	02.04.2004	National basic fee paid
	02.04.2004	Search fee paid
	02.04.2004	Designation fee(s) paid
	02.04.2004	Examination fee paid
Examination procedure	15.03.2003	Request for preliminary examination filed International Preliminary Examining Authority: US
	06.04.2004	Examination requested [2004/29]
	12.02.2008	Amendment by applicant (claims and/or description)
	01.10.2008	Despatch of a communication from the examining division (Time limit: M04)
	09.01.2009	Reply to a communication from the examining division
	04.05.2010	Application deemed to be withdrawn, date of legal effect [2010/46]
	30.06.2010	Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2010/46]
Fees paid	Renewal fee
	14.10.2004	Renewal fee patent year 03
	12.10.2005	Renewal fee patent year 04
	12.10.2006	Renewal fee patent year 05
	12.10.2007	Renewal fee patent year 06
	31.03.2008	Renewal fee patent year 07
	Penalty fee
	Additional fee for renewal fee
	31.10.2009	08 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XDY]WO0069441 (PHARMA MAR SA [ES], et al) [XD] 14-18 * the whole document * [Y] 19;
		[Y]WO0069862 (PHARMA MAR SA [ES], et al) [Y] 15-17,19 * page 47, paragraph 4 - page 50 *;
		[Y]WO0177115 (PHARMA MAR SA [ES], et al) [Y] 15-17,19 * page 32, paragraph 4 - page 33, paragraph 3 * * page 54 - page 57 *;
		[PY]WO0187894 (PHARMA MAR SA [ES], et al) [PY] 15-17,19 * page 1 * * page 10, paragraph L * * page 12 ** pages 85-87,89,90,92,93 *;
		[PX]WO0236135 (PHARMA MAR SA [ES], et al) [PX] 14-18 * the whole document *;
		[XY] - DELALOGE S ET AL, "Ecteinascidin-743: A marine-derived compounds in advanced, pretreated sarcoma patients--preliminary evidence of activity", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, (20010301), vol. 19, no. 5, ISSN 0732-183X, pages 1248 - 1255, XP002959599 [X] 14-18 * the whole document * [Y] 19
		[XDY] - TAAMMA A ET AL, "Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, (20010301), vol. 19, no. 5, ISSN 0732-183X, pages 1256 - 1265, XP002959600 [XD] 14,18 * the whole document * [Y] 15-17,19
		[XDY] - RYAN D P ET AL, "Phase I and pharmacokinetics study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (200102), vol. 7, ISSN 1078-0432, pages 231 - 242, XP002959598 [XD] 14,18 [Y] 15-17,19
		[X] - MARTINEZ E J ET AL, "PHTHALASCIDIN, A SYNTHETIC ANTITUMOR AGENT WITH POTENCY AND MODE OFACTION COMPARABLE TO ECTEINASCIDIN 743", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (199903), vol. 96, no. 7, ISSN 0027-8424, pages 3496 - 3501, XP001026021 [X] 14,18 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.96.7.3496
	International search	[A]US5089273 (RINEHART KENNETH L [US], et al);
		[A]US5256663 (RINEHART KENNETH [US], et al);
		[A]US5478932 (RINEHART KENNETH L [US], et al);
		[A] - RYAN ET AL., "Phase I and pharmacokinetics study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies", CLINICAL CANCER RESEARCH, (2001), vol. 7, pages 231 - 242, XP002959598
		[A] - DELALOGE ET AL., "Ecteinascidin-743: A marine-derived compounds in advanced, pretreated sarcoma patients--preliminary evidence of activity", JOURNAL OF CLINICAL ONCOLOGY, (200103), vol. 19, no. 5, pages 1248 - 1255, XP002959599
		[A] - TAAMMA ET AL., "Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors", JOURNAL OF CLINICAL ONCOLOGY, (200103), vol. 19, no. 5, pages 1256 - 1265, XP002959600

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p